Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Accumulated Expenses (2016 - 2022)

Historic Accumulated Expenses for Cumberland Pharmaceuticals (CPIX) over the last 13 years, with Q4 2022 value amounting to $17.6 million.

  • Cumberland Pharmaceuticals' Accumulated Expenses rose 10289.91% to $17.6 million in Q4 2022 from the same period last year, while for Dec 2022 it was $17.6 million, marking a year-over-year increase of 10289.91%. This contributed to the annual value of $17.6 million for FY2022, which is 10289.91% up from last year.
  • As of Q4 2022, Cumberland Pharmaceuticals' Accumulated Expenses stood at $17.6 million, which was up 10289.91% from $8.7 million recorded in Q4 2021.
  • Cumberland Pharmaceuticals' Accumulated Expenses' 5-year high stood at $17.6 million during Q4 2022, with a 5-year trough of $8.7 million in Q4 2021.
  • For the 5-year period, Cumberland Pharmaceuticals' Accumulated Expenses averaged around $13.1 million, with its median value being $11.3 million (2020).
  • As far as peak fluctuations go, Cumberland Pharmaceuticals' Accumulated Expenses tumbled by 3366.69% in 2019, and later skyrocketed by 10289.91% in 2022.
  • Quarter analysis of 5 years shows Cumberland Pharmaceuticals' Accumulated Expenses stood at $16.7 million in 2018, then plummeted by 33.67% to $11.1 million in 2019, then grew by 1.53% to $11.3 million in 2020, then decreased by 22.98% to $8.7 million in 2021, then skyrocketed by 102.9% to $17.6 million in 2022.
  • Its last three reported values are $17.6 million in Q4 2022, $8.7 million for Q4 2021, and $11.3 million during Q4 2020.